We claim:

1. Use of a 5-HT_4 receptor agonist, in the manufacture of a medicament for the treatment of dementia due to menopause, senile dementia, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, or behavioral and psychological symptoms of dementia, wherein the 5-HT_4 receptor agonist is a compound, Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole or a pharmaceutically acceptable salt thereof.

2. Use of a 5-HT_4 receptor agonist as claimed in claim 1, wherein the pharmaceutically acceptable salt of Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole is selected from mesylate, hydrochloride, oxalate, succinate, fumarate or tartrate salt.

3. Use as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole is Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate.

4. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of dementia due to menopause.

5. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of senile dementia.

6. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cognitive deficits associated with schizophrenia.

7. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of depression.

8. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in combination with a selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of depression.

9. The use as claimed in claim 8, wherein the selective serotonin reuptake inhibitor is selected from paroxetine, citalopram, escitalopram, fluoxetine, sertraline, dapoxetine and vilazodone or a pharmaceutically acceptable salt thereof.

10. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of chemotherapy-induced cognitive impairment.

11. Use of a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for treating behavioral and psychological symptoms of dementia.

12. The use of a 5-HT_4 receptor agonist as claimed in claim 1 or 11, wherein the behavioral and psychological symptom of dementia is selected from apathy/indifference, agitation, aggression, depression, anxiety, irritability/lability, dysphoria, aberrant motor behavior, delusions, hallucinations, elation/euphoria, psychosis, disinhibition, sleep and night time behavior disorders, or appetite and eating disorders.

13. The use of a 5-HT_4 receptor agonist as claimed in claim 11 or claim 12, wherein the behavioral and psychological symptom of dementia is selected from apathy/indifference in Alzheimer's disease, aggression in Alzheimer's disease, agitation in Alzheimer's disease, depression in Alzheimer's disease, anxiety in Alzheimer's disease, irritability/lability in Alzheimer's disease, dysphoria in Alzheimer's disease, aberrant motor behavior in Alzheimer's disease, delusions in Alzheimer's disease, hallucinations in Alzheimer's disease, elation/euphoria in Alzheimer's disease, psychosis in Alzheimer's disease, disinhibition in Alzheimer's disease, sleep and night time behavior disorders in Alzheimer's disease, appetite and eating disorders in Alzheimer's disease, apathy/indifference in Parkinson's disease, aggression in Parkinson's disease, agitation in Parkinson's disease, depression in Parkinson's disease, anxiety in Parkinson's disease, irritability/lability in Parkinson's disease, dysphoria in Parkinson's disease, aberrant motor behavior in Parkinson's disease, delusions in Parkinson's disease, hallucinations in Parkinson's disease, elation/euphoria in Parkinson's disease, psychosis in Parkinson's disease, disinhibition in Parkinson's disease, sleep and night time behavior disorders in Parkinson's disease, or appetite and eating disorders in Parkinson's disease.

14. Use of a pharmaceutical composition comprising a 5-HT_4 receptor agonist as claimed in any one of claims 1 to 3 and pharmaceutically acceptable excipients in the manufacture of a

medicament for the treatment of dementia due to menopause, senile dementia, cognitive deficits in schizophrenia, depression, chemotherapy-induced cognitive impairment, or behavioral and psychological symptoms of dementia.

15. The use of pharmaceutical composition as claimed in claim 14, wherein the medicament is administered to the patient by oral, nasal, local, or parenteral routes.

16. The use of pharmaceutical composition as claimed in claim 14 or claim 15, wherein the medicament is administered to the patient one to three times per day, one to three times per week or one to three times per month.